AR086519A1 - Procedimiento para producir hidrocloruro de epirubicina cristalino e hidrocloruro de epirubicina cristalino producido mediante este procedimiento - Google Patents

Procedimiento para producir hidrocloruro de epirubicina cristalino e hidrocloruro de epirubicina cristalino producido mediante este procedimiento

Info

Publication number
AR086519A1
AR086519A1 ARP120101808A ARP120101808A AR086519A1 AR 086519 A1 AR086519 A1 AR 086519A1 AR P120101808 A ARP120101808 A AR P120101808A AR P120101808 A ARP120101808 A AR P120101808A AR 086519 A1 AR086519 A1 AR 086519A1
Authority
AR
Argentina
Prior art keywords
hydrocloride
procedure
crystalline
epirubicin hydrochloride
epirubicin
Prior art date
Application number
ARP120101808A
Other languages
English (en)
Inventor
Kunnari Tero Dr
Original Assignee
Heraeus Precious Metals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heraeus Precious Metals Gmbh filed Critical Heraeus Precious Metals Gmbh
Publication of AR086519A1 publication Critical patent/AR086519A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/56—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a hidrocloruro de epirubicina cristalino y un procedimiento para su producción. El procedimiento para producir hidrocloruro de epirubicina cristalino comprende las etapas operativas de: (a) provisión de hidrocloruro de epirubicina, (b) producción de una mezcla que contiene el hidrocloruro de epirubicina provisto y al menos un alcohol seleccionado del grupo que comprende 1-butanol, 2-butanol y 1-pentanol, y (c) cristalización del hidrocloruro de epirubicina a partir de esta mezcla.Reivindicación 1: Procedimiento para producir hidrocloruro de epirubicina cristalino, caracterizado porque comprende las etapas operativas: (a) provisión de hidrocloruro de epirubicina, (b) producción de una mezcla que contiene el hidrocloruro de epirubicina provisto y al menos un alcohol seleccionado del grupo que comprende 1-butanol, 2-butanol y 1-pentanol, y (c) cristalización del hidrocloruro de epirubicina a partir de esta mezcla.
ARP120101808A 2011-05-31 2012-05-22 Procedimiento para producir hidrocloruro de epirubicina cristalino e hidrocloruro de epirubicina cristalino producido mediante este procedimiento AR086519A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011103751A DE102011103751A1 (de) 2011-05-31 2011-05-31 Kristallisierung von Epirubicinhydrochlorid
US201161493034P 2011-06-03 2011-06-03

Publications (1)

Publication Number Publication Date
AR086519A1 true AR086519A1 (es) 2013-12-18

Family

ID=47173398

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101808A AR086519A1 (es) 2011-05-31 2012-05-22 Procedimiento para producir hidrocloruro de epirubicina cristalino e hidrocloruro de epirubicina cristalino producido mediante este procedimiento

Country Status (14)

Country Link
US (1) US9657047B2 (es)
EP (1) EP2714707B1 (es)
JP (2) JP6014844B2 (es)
KR (1) KR20140006092A (es)
CN (1) CN103827129A (es)
AR (1) AR086519A1 (es)
AU (1) AU2012265238B2 (es)
DE (1) DE102011103751A1 (es)
HR (1) HRP20170329T1 (es)
HU (1) HUE031795T2 (es)
PL (1) PL2714707T3 (es)
RU (1) RU2586117C2 (es)
TW (1) TWI496789B (es)
WO (1) WO2012163508A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2778171A1 (en) * 2013-03-15 2014-09-17 Synbias Pharma Ltd. Crystalline monohydrate of epirubicin hydrochloride
CN104861014B (zh) * 2015-06-03 2017-09-29 道中道（菏泽）制药有限公司 一种盐酸表阿霉素结晶的制备方法
CN109384822B (zh) * 2017-08-11 2021-08-03 鲁南制药集团股份有限公司 一种盐酸表柔比星晶型及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1506200A (en) 1975-04-30 1978-04-05 Farmaceutici Italia Glycosides
US4345068A (en) 1979-11-22 1982-08-17 Farmitalia Carlo Erba S.P.A. Process for the preparation of 4'-epidaunorubicin, 3',4'-diepidaunorubicin, their doxorubicin analogs, and intermediates used in said process
IT1155446B (it) 1982-12-23 1987-01-28 Erba Farmitalia Procedimento per la purificazione di glucosidi antraciclinonici mediante adsobimento selettivo su resine
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
ATE195526T1 (de) * 1996-12-16 2000-09-15 Pharmachemie Bv Verfahren zur herstellung von epirubicin oder zusatzsalzen davon, von daunorubicin
AU1259899A (en) 1997-11-28 1999-06-16 Sumitomo Pharmaceuticals Company, Limited Crystalline amrubicin hydrochloride
ES2356284T3 (es) * 1997-12-05 2011-04-06 Mercian Corporation Antibiótico de antraciclina cristalino y procedimiento para su producción.
US20020048610A1 (en) * 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
ATE520702T1 (de) * 2003-07-02 2011-09-15 Solux Corp Thermisch stabiles kristallines epirubicin- hydrochlorid und herstellungsverfahren dafür
US20090099346A1 (en) 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride
US7388083B2 (en) * 2005-03-07 2008-06-17 Solux Corporation Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics
CA2606390A1 (en) * 2005-05-11 2006-11-16 Sicor, Inc. Stable lyophilized anthracycline glycosides
US8802830B2 (en) * 2005-12-20 2014-08-12 Solux Corporation Synthesis of epirubicin from 13-dihydrodaunorubicine
JP2007261976A (ja) * 2006-03-28 2007-10-11 Meiji Seika Kaisha Ltd 抗腫瘍性アンスラサイクリン系抗生物質の製造法
ES2644422T3 (es) 2007-05-08 2017-11-28 Provivo Oy Cepas modificadas genéticamente que producen metabolitos de antraciclina útiles como fármacos para el cáncer
EP2315765B1 (en) 2008-06-18 2012-12-19 Lexicon Pharmaceuticals, Inc. Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use
EP2636676A3 (en) * 2009-09-08 2014-01-01 Heraeus Precious Metals GmbH & Co. KG Crystallization of epidaunorubicin x HCl
KR101125460B1 (ko) * 2010-03-24 2012-03-28 동아제약주식회사 에피루비신 염산염의 신규한 결정형
CN102120750B (zh) * 2011-01-30 2013-04-03 山东新时代药业有限公司 一种盐酸表柔比星的纯化方法

Also Published As

Publication number Publication date
JP2016175938A (ja) 2016-10-06
CN103827129A (zh) 2014-05-28
JP6014844B2 (ja) 2016-10-26
AU2012265238B2 (en) 2016-05-12
HRP20170329T1 (hr) 2017-04-21
DE102011103751A1 (de) 2012-12-06
US20120309948A1 (en) 2012-12-06
KR20140006092A (ko) 2014-01-15
EP2714707A1 (de) 2014-04-09
TWI496789B (zh) 2015-08-21
RU2586117C2 (ru) 2016-06-10
HUE031795T2 (en) 2017-08-28
AU2012265238A1 (en) 2014-01-09
RU2013158684A (ru) 2015-07-10
WO2012163508A1 (de) 2012-12-06
PL2714707T3 (pl) 2017-06-30
TW201302773A (zh) 2013-01-16
JP2014515381A (ja) 2014-06-30
EP2714707B1 (de) 2016-12-14
US9657047B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
DOP2021000179A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
BR112014010460A2 (pt) composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
AR066347A1 (es) Gel mezclador para provocar fracturas
BR112014013175A8 (pt) composições de liberação prolongada baseadas em lipídios anfipáticos e processo para preparar comprimidos de composição de liberação prolongada
AR061516A1 (es) Composicion de rebaudiosido a y metodo para purificar el rebaudiosido a
MY167395A (en) Method for producing glufosinate p free acid
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
NI201200140A (es) Hidrato del hidrocloruro de agomelatina y preparación de éste
BR112014013098A2 (pt) composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
BR112015005404A2 (pt) Formas polimórficas de enzalutamida e sua preparação
BRPI1010970A2 (pt) solução farmacêutica, processo para preparar uma solução farmacêutica e método para tratamento
AR090319A1 (es) Biorrefineria integrada
AR066612A1 (es) Metodo para mejorar la calidad de los brotes de una planta
BR112013031307A2 (pt) métodos para tratamento de material lignocelulósico
BR112013022277A2 (pt) método para produção de cadeia de açúcar contendo ácido siálico
BR112013021775A2 (pt) bactéria corineforme, e, método para produzir um l-aminoácido
AR079433A1 (es) Regulacion del crecimiento de las plantas
BR112014008401A2 (pt) processo para a preparação de metoxi melonal
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
BR112017001177A2 (pt) processo para a purificação de poliovírus a partir de culturas celulares
AR086519A1 (es) Procedimiento para producir hidrocloruro de epirubicina cristalino e hidrocloruro de epirubicina cristalino producido mediante este procedimiento
BR112015022859A2 (pt) processo para fabricação de mono-hidrato trissódico gadofosveset
BR112013020212A2 (pt) método de produção de um adoçante natuarl aprimorado
WO2012138463A3 (en) Microfrabication of tunnels

Legal Events

Date Code Title Description
FC Refusal